A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 134, Issue 5, 2008, Pages 528-532

  Lydiatt, William M ^a,c   Denman, David ^a   McNeilly, Dennis P ^a   Puumula, Susan E ^b   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Methodist Hospital Omaha   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEAD AND NECK CANCER; HUMAN; MALE; MENTAL HEALTH; NAUSEA; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; WELLBEING;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SUICIDE;

EID: 44249104205     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.134.5.528     Document Type: Article

References (50)

1. Morton RP, Davies ADM, Baker J, Baker GA, Stell PM. Quality of life in treated head and neck cancer patients: a preliminary report. Clin Otolaryngol Allied Sci. 1984;9(3):181-185.
2. Baile WF, Gilbertini M, Scott L, Endicott J. Depression and tumor stage in cancer of the head and neck. Psychooncology. 1992;1:15-24.
3. de Graeff A, de Leeuw JRJ, Ros WJG, Hordijk G-J, Blijham GH, Winnubst JAM. Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck. 2000;22(4):398-407.
4. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol. 1997;33(3):189-196.
5. de Leeuw JRJ, de Graeff A, Ros WJ, Blijham GH, Hordijk G-J, Winnubst JAM. Prediction of depressive symptomatology after treatment of head and neck cancer: the influence of pre-treatment physical and depressive symptoms, coping, and social support. Head Neck. 2000;22(8):799-807.
6. Sehlen S, Lenk M, Herschbach P, et al. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck. 2003;25(12):1004-1018.
7. Llewellyn CD, McGurk M, Weinman J. Are psycho-social and behavioural factors related to health related-quality of life in patients with head and neck cancer? a systematic review. Oral Oncol. 2005;41(5):440-454.
8. Lydiatt WM, Johnson PJ. Cancers of the Mouth and Throat: A Patient's Guide to Treatment. Omaha, NE: Addicus Books Inc; 2001.
9. Breitbart W, Holland J. Psychosocial aspects of head and neck cancer. Semin Oncol. 1988;15(1):61-69.
10. Frampton M. Psychological distress in patients with head and neck cancer: review. Br J Oral Maxillofac Surg. 2001;39(1):67-70.
11. Gritz ER, Carmack CL, de Moor CL, et al. First year after head and neck cancer: quality of life. J Clin Oncol. 1999;17(1):352-360.
12. Gamba A, Romano M, Grosso IM, et al. Psychosocial adjustment of patients surgically treated for head and neck cancer. Head Neck. 1992;14(3):218-223.
13. Lloyd-Williams M. Difficulties in diagnosing and treating depression in the terminally ill cancer patient. Postgrad Med J. 2000;76(899):555-558.
14. Howard PA, Ellerbeck EF. Optimizing beta-blocker use after myocardial infarction. Am Fam Physician. 2000;62(8):1853-1860.
15. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160(1):41-46.
16. Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from United States clinical trials. J Clin Psychiatry. 2000;61(12):896-908.
17. Parker NG, Brown CS. Citalopram in the treatment of depression. Ann Pharmacother. 2000;34(6):761-771.
18. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997;33(4):771-774.
19. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59(6):493-501.
20. Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/default.asp. Accessed February 26, 2008.
21. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health; 1976.
26. Hassan SJ, Weymuller EA. Assessment of quality of life in head and neck cancer patients. Head Neck. 1993;15(6):485-496.
27. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Arch Gen Psychiatry. 1995;52(2):89-97.
28. Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry. 1990;51(suppl):12-17.
29. Mermelstein HT, Lesko L. Depression in patients with cancer. Psychooncology. 1992;1:199-215.
30. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26(1):3-11.
31. Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol. 1997;44(2):137-141.
32. Le Q, Fu KK, Kroll S. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997;39(1):115-126.
33. Björkenstam C, Edberg A, Ayoubi S, Posen M. Are cancer patients at higher suicide risk than the general population? a nationwide register study in Sweden from 1965 to 1999. Scand J Public Health. 2005;33(3):208-214.
34. Yousaf U, Christensen ML, Engholm G, Storm HH. Suicides among Danish cancer patients 1971-1999. Br J Cancer. 2005;92(6):995-1000.
35. Hem E, Loge JH, Haldorsen T, Ekeberg O. Suicide risk in cancer patients from 1960 to 1999. J Clin Oncol. 2004;22(20):4209-4216.
36. Farberow NL, Ganzler S, Cutter F, et al. An eight year survey of hospital suicides. Life Threat Behav. 1971;1(1):184-201.
37. Allison PJ, Edgar L, Nicolau B, Archer J, Black M, Hier M. Results of a feasibility study for a psycho-educational intervention in head and neck cancer. Psychooncology. 2004;13(7):482-485.
38. Hammerlid E, Persson LO, Sullivan M, Westin T. Quality-of-life effects of psychosocial intervention in patients with head and neck cancer. Otolaryngol Head Neck Surg. 1999;120(4):507-516.
39. Petty F, Kramer G, Wilson L. Prevention of learned helplessness: in vivo correlation with cortical serotonin. Pharmacol Biochem Behav. 1992;43(2):361-367.
40. Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interaction and treatment considerations. J Clin Psychiatry. 1999;60(suppl 4):40-55.
41. Chaturvedi PR, Maguire P, Hopwood P. Antidepressant medication in cancer patients. Psychooncology. 1994;3:57-60.
42. Berney A, Stiefel F, Mazzocato C, Buclin T. Psychopharmacology in supportive care of cancer: a review for the clinician. Support Care Cancer. 2000;8(4):278-286.
43. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med. 2001;344(13):961-966.
44. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89(3):243-249.
45. D'Antonio LL, Long SA, Zimmerman GJ, Peterman AH, Petti GH, Chonkich GD. Relationship between quality of life and depression in patients with head and neck cancer. Laryngoscope. 1998;108(6):806-811.
46. List MA, Mumby P, Haraf D, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res. 1997;6(3):274-284.
47. Hammerlid E, Ahlner-Elmqvist M, Bjordal K, et al. A prospective multicentre study in Sweden and Norway of mental distress and psychiatric morbidity in head and neck cancer patients. Br J Cancer. 1999;80(5-6):766-774.
48. Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer: a longitudinal study. Head Neck. 2001;23(2):113-125.
49. de Graeff A, de Leeuw JRJ, Ros WGJ, Hordijk GJ, Blijham GH, Winnubst JAM. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000;110(1):98-106.
50. Llewellyn CD, McGurk M, Weinman J. Head and neck cancer: to what extent can psychological factors explain differences between health-related quality of life and individual quality of life? Br J Oral Maxillofac Surg. 2006;44(5):351-357.